 | |
| Clinical data | |
|---|---|
| Other names | BNC210; BNC-210; IW2143; IW-2143;L-Isoleucyl-L-tryptophan |
| Routes of administration | Oral |
| Drug class | α7-Nicotinic acetylcholine receptornegative allosteric modulator |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 69.4% (rat)[1][2] |
| Protein binding | 70–88%[1][2] |
| Eliminationhalf-life | 6.2 hours (rat)[1][2] |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H23N3O3 |
| Molar mass | 317.389 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Soclenicant (INNTooltip International Nonproprietary Name),[3] also known by its developmental code namesBNC210 andIW-2143 and asL-isoleucyl-L-tryptophan, is anantinicotinic agent which is under development for the treatment ofanxiety disorders such associal phobia andgeneralized anxiety disorder, as well as for treatment ofagitation,post-traumatic stress disorder (PTSD), anddepressive disorders.[1][4][5] It is takenby mouth.[4]
The drug acts as a highlyselectivenegative allosteric modulator (NAM) of theα7-nicotinic acetylcholine receptor (α7-nAChR).[1][6][4][5] It producesanxiolytic-,anti-stress-, andantidepressant-like effects without causingsedation,memory ormotor impairment, orphysical dependence in rodents.[6] Chemically, soclenicant is adipeptide of theamino acidsL-tryptophan andL-isoleucine and can be considered atryptaminederivative.[7]
Soclenicant is being developed by Bionomics.[4] It has also been developed by Ironwood Pharmaceuticals and EmpathBio.[4][5] Bionomics was acquired by Neuphoria Therapeutics in December 2024.[4] As of December 2024, soclenicant is inphase 3clinical trials for anxiety disorders,phase 2 trials for agitation and PTSD, and no recent development has been reported for depressive disorders.[4][5] The drug receivedFast Track designation from theUnited StatesFood and Drug Administration (FDA) in 2019.[8] It was first described in the literature, in aconference abstract, by 2007.[2]
